| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1146/ANNUREV.BIOCHEM.70.1.341 |
| P698 | PubMed publication ID | 11395411 |
| P2093 | author name string | Willson TM | |
| Kliewer SA | |||
| Lambert MH | |||
| P2860 | cites work | Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension | Q22011018 |
| P1104 | number of pages | 27 | |
| P304 | page(s) | 341-367 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Annual Review of Biochemistry | Q567356 |
| P1476 | title | Peroxisome proliferator-activated receptor gamma and metabolic disease. | |
| P478 | volume | 70 |
| Q27677636 | (+)-Rutamarin as a Dual Inducer of Both GLUT4 Translocation and Expression Efficiently Ameliorates Glucose Homeostasis in Insulin-Resistant Mice |
| Q40226575 | 15-deoxy-(Delta12,14)-prostaglandin J2 (15d-PGJ2) induces cell death through caspase-independent mechanism in A172 human glioma cells |
| Q40810593 | 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis |
| Q100495857 | A New Series of Ferulic Acid Amides Reveals an Unexpected Peroxiredoxin 1 Inhibition Activity With In Vivo Antidiabetic and Hypolipidemic Effects |
| Q28593737 | A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma |
| Q36763993 | A consideration of PPAR-gamma ligands with respect to lipophilicity: current trends and perspectives |
| Q34249161 | A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity |
| Q36536205 | A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes |
| Q39121562 | A systems perspective on brown adipogenesis and metabolic activation. |
| Q38361567 | AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats |
| Q44980680 | Actions of PPARgamma agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids. |
| Q37149978 | Activation of PPARγ by a Natural Flavonoid Modulator, Apigenin Ameliorates Obesity-Related Inflammation Via Regulation of Macrophage Polarization |
| Q44022379 | Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells |
| Q34838292 | Adipogenesis and fat-cell function in obesity and diabetes |
| Q42814976 | Ahnak stimulates BMP2-mediated adipocyte differentiation through Smad1 activation |
| Q40461294 | Alpha,beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor gamma. |
| Q35195941 | Alterations in TCF7L2 expression define its role as a key regulator of glucose metabolism |
| Q35639785 | Alternative mRNA splicing of corepressors generates variants that play opposing roles in adipocyte differentiation. |
| Q28086892 | Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms |
| Q42469480 | An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. |
| Q39835267 | Anandamide increases the differentiation of rat adipocytes and causes PPARgamma and CB1 receptor upregulation |
| Q42491731 | Anti-angiogenic action of PPARγ ligand in human umbilical vein endothelial cells is mediated by PTEN upregulation and VEGFR-2 downregulation |
| Q37686356 | Anti-apoptotic actions of PPAR-gamma against ischemic stroke |
| Q34330155 | Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. |
| Q46983586 | Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor gamma-activated maxi-K channel opening in human umbilical vein endothelial cells |
| Q35230678 | Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation |
| Q39950463 | Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines |
| Q24318657 | Apolipoprotein C-III: understanding an emerging cardiovascular risk factor |
| Q35586837 | Aromatase and cyclooxygenases: enzymes in breast cancer |
| Q34470467 | Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. |
| Q34490355 | Association of variants in genes related to the immune response and obesity with BPH in CLUE II |
| Q27653218 | Atomic structure of mutant PPARgamma LBD complexed with 15d-PGJ2: novel modulation mechanism of PPARgamma/RXRalpha function by covalently bound ligands |
| Q44349478 | Beneficial effects of β-conglycinin on renal function and nephrin expression in early streptozotocin-induced diabetic nephropathy rats |
| Q64325520 | Bicyclic eremophilane-type petasite sesquiterpenes potentiate peroxisome proliferator-activated receptor γ activator-mediated inhibition of dendritic cells |
| Q39224484 | C-Peptide and its intracellular signaling |
| Q34540591 | C-peptide and diabetic kidney disease |
| Q37302225 | C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists |
| Q44780691 | CDDO induces apoptosis via the intrinsic pathway in lymphoid cells. |
| Q35630715 | Circulating and dietary trans fatty acids and incident type 2 diabetes in older adults: the Cardiovascular Health Study |
| Q35887411 | Combined thiazolidinedione-insulin therapy: should we be concerned about safety? |
| Q33797616 | Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes |
| Q37122445 | Consecutive positive feedback loops create a bistable switch that controls preadipocyte-to-adipocyte conversion |
| Q42512618 | Coordinated transcriptional control of adipocyte triglyceride lipase (Atgl) by transcription factors Sp1 and peroxisome proliferator-activated receptor γ (PPARγ) during adipocyte differentiation. |
| Q37265280 | Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors |
| Q46867693 | Correlation between porcine PPARGC1A mRNA expression and its downstream target genes in backfat and longissimus dorsi muscle. |
| Q26824893 | Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? |
| Q41832154 | Current and novel therapies for the treatment of nonalcoholic steatohepatitis |
| Q35611068 | Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists. |
| Q42806855 | Differentiation-dependent regulation of the cyclooxygenase cascade during adipogenesis suggests a complex role for prostaglandins |
| Q37633561 | Dissecting the brown adipogenic regulatory network using integrative genomics |
| Q36931609 | Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders |
| Q40739285 | Dual action of isoprenols from herbal medicines on both PPARgamma and PPARalpha in 3T3-L1 adipocytes and HepG2 hepatocytes |
| Q35407199 | Early pharmacological inhibition of angiotensin-I converting enzyme activity induces obesity in adulthood |
| Q30472847 | Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome |
| Q43108533 | Effect of rosiglitazone on cisplatin-induced nephrotoxicity |
| Q34919583 | Effects of age and dysfunction on human meibomian glands. |
| Q40560414 | Effects of rosiglitazone treatment on the pentose phosphate pathway and glutathione-dependent enzymes in liver and kidney of rats fed a high-fat diet |
| Q33727061 | Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus |
| Q39686417 | Effects of the insulin sensitizing drug, pioglitazone, and lipopolysaccharide administration on markers of systemic inflammation and clinical parameters in horses |
| Q36905154 | Effects of thiazolidinediones on blood pressure |
| Q35578270 | Enzymology and Molecular Biology of Glucocorticoid Metabolism in Humans |
| Q79745372 | Expression of ectonucleotide pyrophosphate phosphodiesterase and peroxisome proliferator activated receptor gamma in morbidly obese patients |
| Q44471149 | Fatty acids modulate the effect of darglitazone on macrophage CD36 expression. |
| Q40895648 | Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. |
| Q38408437 | Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin |
| Q38022356 | Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma |
| Q27679090 | GQ-16, a Novel Peroxisome Proliferator-activated Receptor (PPAR ) Ligand, Promotes Insulin Sensitization without Weight Gain |
| Q36267948 | Genes involved in obesity: Adipocytes, brain and microflora |
| Q37408562 | Genetic variations in peroxisome proliferator-activated receptor gamma expression affect blood pressure |
| Q91339440 | How to reprogram microglia toward beneficial functions |
| Q46479941 | Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPAR(gamma):RXR heterodimers: comparison with other polyunsaturated fatty acids |
| Q36447407 | Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy |
| Q39772693 | IL-10 mediates rosiglitazone-induced kidney protection in cisplatin nephrotoxicity |
| Q90073276 | Identification and Characterization of Cannabimovone, a Cannabinoid from Cannabis sativa, as a Novel PPARγ Agonist via a Combined Computational and Functional Study |
| Q90448406 | Identification and structural insight of an effective PPARγ modulator with improved therapeutic index for anti-diabetic drug discovery |
| Q41910885 | Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes |
| Q37609686 | Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro. |
| Q35237706 | Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis |
| Q40576825 | Impact and Therapeutic Potential of PPARs in Alzheimer's Disease |
| Q46503090 | Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient |
| Q26866480 | Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets |
| Q38471509 | Influence of quercetin-rich onion peel extracts on adipokine expression in the visceral adipose tissue of rats |
| Q34315365 | Inhibition of cancer cell proliferation by PPARγ is mediated by a metabolic switch that increases reactive oxygen species levels |
| Q37225357 | Integration of metabolism and inflammation by lipid-activated nuclear receptors |
| Q42513731 | Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes |
| Q21342827 | Intracellular signalling by C-peptide |
| Q36512559 | Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes |
| Q36695847 | Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines |
| Q33602487 | Leptin revisited: its mechanism of action and potential for treating diabetes |
| Q81422309 | Ligand-escape pathways from the ligand-binding domain of PPARgamma receptor as probed by molecular dynamics simulations |
| Q34671576 | Lipid management in diabetic patients: lessons from prevention trials |
| Q27013011 | Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity |
| Q41064444 | Lotus Leaf Aqueous Extract Reduces Visceral Fat Mass and Ameliorates Insulin Resistance in HFD-Induced Obese Rats by Regulating PPARγ2 Expression |
| Q35794061 | Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones |
| Q35222047 | Macrophage-specific expression of human lysosomal acid lipase corrects inflammation and pathogenic phenotypes in lal-/- mice. |
| Q24529989 | Mechanisms of phthalate ester toxicity in the female reproductive system |
| Q27679376 | Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists |
| Q36622931 | Metabolic control of the Treg/Th17 axis |
| Q44776756 | Metabolic effects of Troglitazone in patients with diet-controlled type 2 diabetes |
| Q26770105 | Molecular Regulation of Adipogenesis and Potential Anti-Adipogenic Bioactive Molecules |
| Q37338210 | Moringin activates Wnt canonical pathway by inhibiting GSK3β in a mouse model of experimental autoimmune encephalomyelitis |
| Q35745608 | Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. |
| Q42728024 | Neuroprotection by rosiglitazone in transient focal cerebral ischemia might not be mediated by glutamate transporter-1. |
| Q33935032 | Novel PPARγ partial agonists with weak activity and no cytotoxicity; identified by a simple PPARγ ligand screening system |
| Q45247890 | Nuclear receptor peroxisome proliferator-activated receptor-gamma is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen |
| Q36852547 | Nuclear receptor signalling in dendritic cells connects lipids, the genome and immune function |
| Q26825692 | Nuclear receptors and their selective pharmacologic modulators |
| Q42125206 | PPAR Could Contribute to the Pathogenesis of Hepatocellular Carcinoma |
| Q37553185 | PPAR and Pain |
| Q36426786 | PPAR-gamma in the Cardiovascular System |
| Q41938308 | PPAR-gamma, Microglial Cells, and Ocular Inflammation: New Venues for Potential Therapeutic Approaches |
| Q46314621 | PPAR-gamma-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules. |
| Q51491070 | PPAR-gamma2 Pro12Ala variant, insulin resistance and plasma long-chain polyunsaturated fatty acids in childhood obesity. |
| Q26863678 | PPAR-γ -- a possible drug target for complicated pregnancies |
| Q33572403 | PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China |
| Q35458969 | PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling. |
| Q28574968 | PPARgamma agonism increases rat adipose tissue lipolysis, expression of glyceride lipases, and the response of lipolysis to hormonal control |
| Q37215869 | PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease |
| Q40371669 | PPARgamma agonists do not directly enhance basal or insulin-stimulated Na(+) transport via the epithelial Na(+) channel |
| Q72999922 | PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? |
| Q35144057 | PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages |
| Q37764531 | PPARgamma in adipocyte differentiation and metabolism--novel insights from genome-wide studies |
| Q36693982 | PPARgamma, a lipid-activated transcription factor as a regulator of dendritic cell function |
| Q24794438 | PPARgamma, neuroinflammation, and disease |
| Q36791361 | PPARs and molecular mechanisms of transrepression |
| Q40288794 | PPARs in Alzheimer's Disease |
| Q37738780 | PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism |
| Q30006155 | PPARγ Agonists Attenuate Trigeminal Neuropathic Pain |
| Q37649336 | PPARγ Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue |
| Q38227702 | PPARγ and PGC-1α as therapeutic targets in Parkinson's |
| Q28069549 | PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease |
| Q89552798 | PPM1A Controls Diabetic Gene Programming through Directly Dephosphorylating PPARγ at Ser273 |
| Q35955186 | PTPRD silencing by DNA hypermethylation decreases insulin receptor signaling and leads to type 2 diabetes |
| Q42574886 | Paracrine Regulation of Angiogenesis and Adipocyte Differentiation During In Vivo Adipogenesis |
| Q24685818 | Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma |
| Q42397418 | Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors. |
| Q34271250 | Peroxisome proliferator activated receptor-γ and traumatic brain injury. |
| Q37995569 | Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders |
| Q40298113 | Peroxisome proliferator-activated receptor gamma ligands stimulate myeloid differentiation and lipogenensis in human leukemia NB4 cells. |
| Q33247258 | Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells |
| Q36918509 | Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases |
| Q44848225 | Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element |
| Q35688221 | Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? |
| Q37412297 | Peroxisome proliferator-activated receptors in diabetic nephropathy |
| Q35212744 | Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression? |
| Q35039274 | Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors |
| Q44965022 | Pharmacokinetics of pioglitazone after multiple oral dose administration in horses |
| Q33744181 | Pharmacophore-driven identification of PPARγ agonists from natural sources. |
| Q80525197 | Pioglitazone and nonalcoholic steatohepatitis |
| Q28580246 | Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats |
| Q34309135 | Pioglitazone modulates the proliferation and apoptosis of vascular smooth muscle cells via peroxisome proliferators-activated receptor-gamma |
| Q46982956 | Pioglitazone. Review of its metabolic and systemic effects |
| Q46883819 | Pioglitazone: a review of its use in type 2 diabetes mellitus |
| Q37142044 | Pleiotropic effects of thiazolidinediones |
| Q38272127 | Pleiotropic role of PPARγ in intracerebral hemorrhage: an intricate system involving Nrf2, RXR, and NF-κB. |
| Q35842790 | Post-translational modifications of nuclear receptors and human disease |
| Q38809165 | Potent PPARγ Ligands from Swietenia macrophylla Are Capable of Stimulating Glucose Uptake in Muscle Cells. |
| Q28066552 | Potential of Natural Products in the Inhibition of Adipogenesis through Regulation of PPARγ Expression and/or Its Transcriptional Activity |
| Q36444597 | Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo |
| Q44414175 | Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-γ expression in splenic T cells |
| Q44332739 | Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and risk of prostate cancer among men in a large cancer prevention study |
| Q36554451 | Protection of the kidney by thiazolidinediones: an assessment from bench to bedside |
| Q37433259 | Pseudoginsenoside F11, a Novel Partial PPAR γ Agonist, Promotes Adiponectin Oligomerization and Secretion in 3T3-L1 Adipocytes |
| Q54946092 | Pulmonary Arterial Hypertension and Insulin Resistance. |
| Q39837073 | Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents |
| Q34856939 | Rationale for and role of thiazolidinediones in type 2 diabetes mellitus |
| Q36407304 | Recent findings concerning thiazolidinediones in the treatment of diabetes |
| Q33420391 | Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation |
| Q37157531 | Regulation of Glial Cell Functions by PPAR-gamma Natural and Synthetic Agonists. |
| Q36995029 | Regulation of Wnt/beta-catenin pathway by cPLA2alpha and PPARdelta |
| Q36254439 | Regulation of small ubiquitin-like modifier-1, nuclear receptor coreceptor, histone deacetylase 3, and peroxisome proliferator-activated receptor-γ in human adipose tissue |
| Q34575468 | Relevance of TNBS-colitis in rats: a methodological study with endoscopic, histologic and Transcriptomic [corrected] characterization and correlation to IBD. |
| Q40455776 | Removal of serum factors by charcoal treatment promotes adipogenesis via a MAPK-dependent pathway. |
| Q35109744 | Resistin: molecular history and prognosis |
| Q35191573 | Resolving the Two "Bony" Faces of PPAR-gamma. |
| Q33440398 | Role of G protein-coupled receptor kinase-2 in peroxisome proliferator-activated receptor gamma-mediated modulation of blood pressure and renal vascular reactivity in SHR. |
| Q37997005 | Role of PPARs in Trypanosoma cruzi Infection: Implications for Chagas Disease Therapy |
| Q35168497 | Roles of 5'-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis |
| Q47802906 | Rosiglitazone Regulates TLR4 and Rescues HO-1 and NRF2 Expression in Myometrial and Decidual Macrophages in Inflammation-Induced Preterm Birth. |
| Q46611073 | Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. |
| Q36157326 | Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone |
| Q54311344 | Rosiglitazone modulates the behaviors of diabetic host-derived fibroblasts in a carboxymethyllysine-modified collagen model. |
| Q46034890 | Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation. |
| Q24535573 | SDP1 is a peroxisome-proliferator-activated receptor gamma 2 co-activator that binds through its SCAN domain |
| Q36497213 | SMRT-GPS2 corepressor pathway dysregulation coincides with obesity-linked adipocyte inflammation |
| Q47696944 | Screening of molecular cell targets for carcinogenic heterocyclic aromatic amines by using CALUX® reporter gene assays |
| Q24793556 | Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats |
| Q40360288 | Spectroscopic analyses of the binding kinetics of 15d-PGJ2 to the PPARgamma ligand-binding domain by multi-wavelength global fitting |
| Q42925474 | Stimulation of ENaC Activity by Rosiglitazone is PPARγ-Dependent and Correlates with SGK1 Expression Increase |
| Q61697352 | Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity |
| Q37120932 | Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs |
| Q64923743 | Sulfuretin Prevents Obesity and Metabolic Diseases in Diet Induced Obese Mice. |
| Q38920687 | Supplementation of omega 3 fatty acids improves oxidative stress in activated BV2 microglial cell line |
| Q44586126 | Synthesis of a high-affinity fluorescent PPARgamma ligand for high-throughput fluorescence polarization assays |
| Q41828132 | Synthesis of a novel thiazolidinedione and evaluation of its modulatory effect on IFN- γ , IL-6, IL-17A, and IL-22 production in PBMCs from rheumatoid arthritis patients. |
| Q46074706 | Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. |
| Q40747044 | T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities |
| Q33809886 | Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs |
| Q26852726 | Targeting inflammation in diabetes: Newer therapeutic options |
| Q37570577 | Targeting insulin sensitivity in the treatment of polycystic ovary syndrome |
| Q35714622 | Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity |
| Q42778982 | Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase |
| Q38016858 | The Current Knowledge of the Role of PPAR in Hepatic Ischemia-Reperfusion Injury. |
| Q34035340 | The Role of Peroxisome Proliferator-Activated Receptor beta/delta on the Inflammatory Basis of Metabolic Disease. |
| Q38254887 | The association between lipid metabolism gene polymorphisms and nephropathy in type 2 diabetes: a meta-analysis |
| Q35212543 | The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease |
| Q38323767 | The effect of troglitazone on lipid accumulation and related gene expression in Hanwoo muscle satellite cell. |
| Q36545395 | The effects of thiazolidinediones on blood pressure levels - a systematic review |
| Q35164460 | The first completed genome sequence from a teleost fish (Fugu rubripes) adds significant diversity to the nuclear receptor superfamily |
| Q34986351 | The macrophage foam cell as a target for therapeutic intervention |
| Q34208083 | The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation |
| Q34772498 | The peroxisome proliferator-activated receptor alpha (PPARalpha): role in hepatocarcinogenesis |
| Q28585701 | The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin |
| Q34838209 | The role of PPARs in atherosclerosis |
| Q45929326 | The role of peroxisome proliferator-activated receptor gamma in blood pressure regulation. |
| Q37848841 | The safety of thiazolidinediones |
| Q36328530 | The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). |
| Q28742884 | The ε3 and ε4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice |
| Q40444038 | Thiazolidinedione (pioglitazone) blocks P. gingivalis- and F. nucleatum, but not E. coli, lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in adipocytes |
| Q37142138 | Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update |
| Q38641190 | Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future |
| Q33585657 | Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications |
| Q36283538 | Thiazolidinediones and inflammation |
| Q33948063 | Thiazolidinediones are partial agonists for the glucocorticoid receptor |
| Q36996294 | Thiazolidinediones as anti-inflammatory and anti-atherogenic agents |
| Q36484662 | Thiazolidinediones: effects on insulin resistance and the cardiovascular system |
| Q34430709 | Thrap3 docks on phosphoserine 273 of PPARγ and controls diabetic gene programming |
| Q24303852 | Transcription factors and nuclear receptors interact with the SWI/SNF complex through the BAF60c subunit |
| Q90231446 | Transcriptional Analysis of FOXO1, C/EBP-α and PPAR-γ2 Genes and Their Association with Obesity-Related Insulin Resistance |
| Q34637612 | Transcriptional regulation of hepatic stellate cell activation |
| Q52678882 | Troglitazone induces differentiation in Trypanosoma brucei. |
| Q40610380 | Tumor necrosis factor-alpha inhibits peroxisome proliferator-activated receptor gamma activity at a posttranslational level in hepatic stellate cells |
| Q36494764 | Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs |
| Q44294516 | Visceral fat and liver fat are independent predictors of metabolic risk factors in men. |
| Q38717181 | WIP1 phosphatase is a critical regulator of adipogenesis through dephosphorylating PPARγ serine 112. |
| Q55658411 | Water Pharmacophore: Designing Ligands using Molecular Dynamics Simulations with Water. |
| Q47855337 | Weak bones in diabetes mellitus - an update on pharmaceutical treatment options |
| Q65001385 | Withaferin A inhibits adipogenesis in 3T3-F442A cell line, improves insulin sensitivity and promotes weight loss in high fat diet-induced obese mice. |
| Q33885244 | Zinc-chelated Vitamin C Stimulates Adipogenesis of 3T3-L1 Cells |
Search more.